List view / Grid view
3 September 2014 | By European Medicines Agency
The European Medicines Agency is pleased to announce two new appointments to its management team...
3 September 2014 | By Teva
Court decision invalidating AZ's patent supports Teva’s launch of DuoResp Spiromax® in UK...
3 September 2014 | By Novartis
Novartis announced that new analyses to be presented at the Joint ACTRIMS-ECTRIMS Meeting in Boston, USA from September 10-13, 2014...
3 September 2014 | By Merck
Merck announced the presentation of data from ongoing clinical trials evaluating the anti-tumor activity of pembrolizumab, the company’s investigational anti-PD-1 antibody...
3 September 2014 | By Amgen
First Marketing Authorization Application for an oncolytic immunotherapy in the European Union...
3 September 2014 | By Andrew Lloyd & Associates
CleveXel Pharma announces that the company has entered into a new partnering agreement with Guilin Pharmaceutical, a Chinese company located in Shanghai, regarding the development of two new products...
2 September 2014 | By Sanofi
Sanofi and Regeneron Pharmaceuticals, Inc. announced detailed positive results from four Phase 3 ODYSSEY trials of alirocumab in people with hypercholesterolemia...
2 September 2014 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced details of the application for its Take a New Challenge for Drug Discovery Global Programme 2014, a collaborative drug discovery initiative for universities and research institutes in Europe...
2 September 2014 | By Daiichi Sankyo
A SGLT2 inhibitor for Type2 Diabetes Mellitus...
2 September 2014 | By Roche
The cobas 6800/8800 Systems offer advanced performance with next generation donor screening assays...
1 September 2014 | By Novo Nordisk
Novo Nordisk announced that in Mexico, as the first country in the world, Ryzodeg® is now launched and made available for people with type 2 diabetes...
1 September 2014 | By Roche
Roche announced that it has commenced a cash tender offer for all outstanding shares of common stock of InterMune, Inc. at a price of US$74.00 per share...
1 September 2014 | By AstraZeneca
Results are in line with new ESC/EACTS 2014 Guidelines on Myocardial Revascularisation which give a class I recommendation to start dual antiplatelet therapy in STEMI patients at first medical contact...
1 September 2014 | By Boehringer Ingelheim
The European Respiratory Society International Congress, in Munich, Germany, September 6-10, 2014 sets the scene for important announcements across the substantial Boehringer Ingelheim respiratory portfolio...
29 August 2014 | By Pfizer
...for intravenous use for the treatment of type 1 Gaucher disease.
